TY - JOUR T1 - Treatment of intracranial aneurysms using the pipeline flex embolization device with shield technology: angiographic and safety outcomes at 1-year follow-up JF - Journal of NeuroInterventional Surgery JO - J NeuroIntervent Surg SP - 396 LP - 399 DO - 10.1136/neurintsurg-2018-014204 VL - 11 IS - 4 AU - Mario Martínez-Galdámez AU - Saleh M Lamin AU - Konstantinos G Lagios AU - Thomas Liebig AU - Elisa F Ciceri AU - Rene Chapot AU - Luc Stockx AU - Swarupsinh Chavda AU - Christoph Kabbasch AU - Giuseppe Faragò AU - Hannes Nordmeyer AU - Thierry Boulanger AU - Mariangela Piano AU - Edoardo P Boccardi Y1 - 2019/04/01 UR - http://jnis.bmj.com/content/11/4/396.abstract N2 - Purpose The Pipeline Embolization Device (PED) is a routine first-line treatment option for intracranial aneurysms (IAs). The Pipeline Flex Embolization Device with Shield Technology (Pipeline Shield) is an updated version of the PED which has been modified to include a surface phosphorylcholine biocompatible polymer. Its early technical success and safety have been reported previously. Here, we assessed the long-term safety and efficacy of the Pipeline Shield for the treatment of IAs.Materials and methods The Pipeline Flex Embolization Device with Shield Technology (PFLEX) study was a prospective, single-arm, multicenter study for the treatment of unruptured IAs using the Pipeline Shield. The primary endpoint was a major stroke in the territory supplied by the treated artery or neurologic death at 1-year post-procedure. Angiographic outcomes were also assessed by an independent radiology laboratory at 6 months and 1 year.Results Fifty patients (mean age, 53 years; 82% female) with 50 unruptured IAs were treated. Mean aneurysm diameter was 8.82±6.15 mm. Of the target aneurysms, 38/50 (76%) were small (<10 mm), 11/50 (22%) were large (≥10 and<25 mm), and 1/50 (2%) was giant (≥25 mm). Forty-seven (94%) were located in the internal carotid artery and three (6%) in the vertebral artery. At 1-year post-procedure, no major strokes or neurologic deaths were reported, and complete occlusion was achieved in 27/33 (81.8%). There were no instances of aneurysm recurrence or retreatment.Conclusions Our 1-year follow-up concerning angiographic and safety outcomes corroborate previous evidence that the Pipeline Shield is a safe and effective treatment for IAs.Trial registration number NCT02390037 ER -